Sentien Biotechnologies, Inc. is a venture-backed, clinical-stage company developing novel approaches to cell therapy. Its lead product, SBI-101, combines mesenchymal stromal cells (MSCs) within an approved blood-filtration device.
By immobilizing MSCs within a blood-contacting device, SBI-101 allows for controlled, dynamic interaction of MSCs and a patient’s bloodstream to invoke a durable wound-healing response throughout the entire body. This technology integrates seamlessly with ex vivo blood circuits commonly used in critical care settings, such as dialysis.
Sentien has initiated a randomized, controlled Phase 1/2 clinical trial of SBI-101 to treat patients with Acute Kidney Injury (AKI) requiring Continuous Renal Replacement Therapy. Results from the 32-patient study are expected in 2018. Sentien closed a $12M Series A financing in April 2017, which was co-led by Boehringer Ingelheim Venture Fund USA, Inc. and BioInnovation Capital, and joined by Chiesi Ventures, MBL Venture Capital Co., Ltd, and Mass Medical Angels.